KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BioNTech SE (BNTX) FCF Margin: 2018-2025

Historic FCF Margin for BioNTech SE (BNTX) over the last 7 years, with Sep 2025 value amounting to 51.40%.

  • BioNTech SE's FCF Margin rose 10272.00% to 51.40% in Q3 2025 from the same period last year, while for Sep 2025 it was -6.73%, marking a year-over-year decrease of 5585.00%. This contributed to the annual value of -2.86% for FY2024, which is 13698.00% down from last year.
  • BioNTech SE's FCF Margin amounted to 51.40% in Q3 2025, which was down 8.50% from 56.17% recorded in Q2 2025.
  • BioNTech SE's FCF Margin's 5-year high stood at 2,615.80% during Q2 2023, with a 5-year trough of -427.08% in Q1 2025.
  • Moreover, its 3-year median value for FCF Margin was 51.40% (2025), whereas its average is 308.76%.
  • In the last 5 years, BioNTech SE's FCF Margin skyrocketed by 249,320bps in 2023 and then crashed by 135,147bps in 2024.
  • Quarterly analysis of 5 years shows BioNTech SE's FCF Margin stood at 3.61% in 2021, then skyrocketed by 1,578bps to 19.38% in 2022, then spiked by 3,815bps to 57.53% in 2023, then slumped by 9,646bps to -38.93% in 2024, then soared by 10,272bps to 51.40% in 2025.
  • Its FCF Margin stands at 51.40% for Q3 2025, versus 56.17% for Q2 2025 and -427.08% for Q1 2025.